WO2016005564A3 - Anticorps dirigés contre le facteur v activé - Google Patents

Anticorps dirigés contre le facteur v activé Download PDF

Info

Publication number
WO2016005564A3
WO2016005564A3 PCT/EP2015/065848 EP2015065848W WO2016005564A3 WO 2016005564 A3 WO2016005564 A3 WO 2016005564A3 EP 2015065848 W EP2015065848 W EP 2015065848W WO 2016005564 A3 WO2016005564 A3 WO 2016005564A3
Authority
WO
WIPO (PCT)
Prior art keywords
activated factor
antibodies against
against activated
factor
fva
Prior art date
Application number
PCT/EP2015/065848
Other languages
English (en)
Other versions
WO2016005564A2 (fr
Inventor
Heidi Lindgreen Holmberg
Gustav RØDER
Kristoffer Winther BALLING
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of WO2016005564A2 publication Critical patent/WO2016005564A2/fr
Publication of WO2016005564A3 publication Critical patent/WO2016005564A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des anticorps monoclonaux ou des fragments de ceux-ci, qui se lient au Facteur V activé (FVa), qu présentent un effet pro-coagulant, ainsi que leurs utilisations thérapeutiques.
PCT/EP2015/065848 2014-07-11 2015-07-10 Anticorps dirigés contre le facteur v activé WO2016005564A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14176717 2014-07-11
EP14176717.8 2014-07-11

Publications (2)

Publication Number Publication Date
WO2016005564A2 WO2016005564A2 (fr) 2016-01-14
WO2016005564A3 true WO2016005564A3 (fr) 2016-04-07

Family

ID=51162604

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/065848 WO2016005564A2 (fr) 2014-07-11 2015-07-10 Anticorps dirigés contre le facteur v activé

Country Status (3)

Country Link
AR (1) AR101185A1 (fr)
TW (1) TW201617371A (fr)
WO (1) WO2016005564A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019071116A1 (fr) * 2017-10-05 2019-04-11 Epivax, Inc. Épitopes de lymphocytes t régulateurs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910576A (en) * 1994-02-14 1999-06-08 Rijks Universiteit Leiden Method for screening for the presence of a genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein
WO2005111075A2 (fr) * 2004-05-18 2005-11-24 University Of Vermont And State Agricultural College Structure cristalline de facteur vai et procede d'identification de modulateurs de facteurs sanguins va
WO2007101106A2 (fr) * 2006-02-23 2007-09-07 The Children's Hospital Of Philadelphia Compositions et méthodes pour moduler une hémostase au moyen de différentes formes de facteur v activé
WO2008067056A2 (fr) * 2006-10-16 2008-06-05 Novelmed Therapeutics, Inc. Procédé d'inhibition de la coagulation avec des anticorps anti-facteur va humains et utilisation de ceux-ci

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910576A (en) * 1994-02-14 1999-06-08 Rijks Universiteit Leiden Method for screening for the presence of a genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein
WO2005111075A2 (fr) * 2004-05-18 2005-11-24 University Of Vermont And State Agricultural College Structure cristalline de facteur vai et procede d'identification de modulateurs de facteurs sanguins va
WO2007101106A2 (fr) * 2006-02-23 2007-09-07 The Children's Hospital Of Philadelphia Compositions et méthodes pour moduler une hémostase au moyen de différentes formes de facteur v activé
WO2008067056A2 (fr) * 2006-10-16 2008-06-05 Novelmed Therapeutics, Inc. Procédé d'inhibition de la coagulation avec des anticorps anti-facteur va humains et utilisation de ceux-ci

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANNETTE VON DRYGALSKI ET AL: "Superior in Vivo Hemostatic Properties of an Engineered Factor Va Variant for Hemophilia Mice", vol. 120, no. 21, 1 November 2012 (2012-11-01), XP002722413, ISSN: 0006-4971, Retrieved from the Internet <URL:https://ash.confex.com/ash/2012/webprogram/Paper50002.html> [retrieved on 20150917] *
KALAFATIS M ET AL: "Contribution of the heavy and light chains of factor Va to the interaction with factor Xa", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 33, no. 21, 31 May 1994 (1994-05-31), pages 6538 - 6545, XP002590638, ISSN: 0006-2960 *
KENNETH SEGERS ET AL: "Coagulation factor V and thrombophilia: Background and mechanisms", THROMBOSIS AND HAEMOSTASIS, vol. 98, no. 3, 17 October 2007 (2007-10-17), pages 530 - 42, XP055175994, ISSN: 0340-6245, DOI: 10.1160/TH07-02-0150 *
SCHLACHTERMAN A ET AL: "Factor V Leiden improves in vivo hemostasis in murine hemophilia models", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUBLISHING, OXFORD, GB, vol. 3, no. 12, 1 December 2005 (2005-12-01), pages 2730 - 2737, XP008130621, ISSN: 1538-7933, DOI: 10.1111/J.1538-7836.2005.01639.X *
SUHNG WOOK KIM ET AL: "Identification of Functionally Important Amino Acid Residues within the C2-Domain of Human Factor V Using Alanine-Scanning Mutagenesis +", BIOCHEMISTRY, vol. 39, no. 8, 1 February 2000 (2000-02-01), pages 1951 - 1958, XP055171137, ISSN: 0006-2960, DOI: 10.1021/bi992256r *
W B FOSTER ET AL: "Monoclonal Antibodies Selective for Activated Factor V", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 258, no. 9, 10 March 1983 (1983-03-10), pages 5606 - 5613, XP055177012, Retrieved from the Internet <URL:http://www.jbc.org/content/258/9/5608.full.pdf> [retrieved on 20150316] *

Also Published As

Publication number Publication date
WO2016005564A2 (fr) 2016-01-14
TW201617371A (zh) 2016-05-16
AR101185A1 (es) 2016-11-30

Similar Documents

Publication Publication Date Title
PH12017502180A1 (en) Tau-binding antibodies
WO2015112886A3 (fr) Protéines de liaison et leurs procédés d&#39;utilisation
WO2017087901A3 (fr) Anticorps anti-lag3, compositions comprenant des anticorps anti-lag3 et méthodes de production et d&#39;utilisation d&#39;anticorps anti-lag3
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
WO2016191643A3 (fr) Agents de liaison à tigit et leurs utilisations
EA201791485A1 (ru) Анти-cd47-антитела и их применения
MX2020010530A (es) Anticuerpos humanizados contra cd269 (bcma).
MX2017011281A (es) Conjugados de amatoxina y anticuerpos.
PH12017502207A1 (en) Tau-binding antibodies
WO2015197823A3 (fr) Anticorps et fragments de liaison à l&#39;antigène qui se lient spécifiquement à la protéine tau associée aux microtubules
EP3176181A4 (fr) Anticorps monoclonal anti-ctla4 ou fragment de celui-ci se liant à l&#39;antigène, composition médicinale et son utilisation
WO2016014974A3 (fr) Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispécifiques, anticorps anti-cd3 activables multispécifiques et procédés d&#39;utilisation de ces anticorps
EP3353213A4 (fr) Nouvel anticorps anti-mésothéline et composition le comprenant
WO2016054598A3 (fr) Anticorps qui se lient à la glycoprotéine du virus ébola et utilisations associés
WO2016004389A3 (fr) Protéines de liaison monovalentes
SG10201909716RA (en) Modified j-chain
WO2016055432A3 (fr) Traitement combiné d&#39;anticorps bispécifiques spécifiques de fap et dr5 et agents chimiothérapeutiques
WO2014163714A3 (fr) Conjugués médicament-anticorps
WO2015075269A9 (fr) Anticorps dirigés contre ccr9 et leurs applications
WO2017019957A3 (fr) Protéines de liaison et leurs procédés d&#39;utilisation
MX2017007747A (es) Anticuerpos para il-17c.
WO2017044866A3 (fr) Administration améliorée de médicaments au cerveau
WO2016007919A3 (fr) Fragments d&#39;anticorps pour détecter un cancer et méthodes d&#39;utilisation
EP3150632A3 (fr) Anticorps anti-ricine et leurs utilisations
WO2016005564A3 (fr) Anticorps dirigés contre le facteur v activé

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15736498

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15736498

Country of ref document: EP

Kind code of ref document: A2